ELI LILLY AND CO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and what generic alternatives to ELI LILLY AND CO drugs are available?
ELI LILLY AND CO has seven approved drugs.
There are eighteen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.
There are three hundred and forty-nine patent family members on ELI LILLY AND CO drugs in fifty-five countries and forty-four supplementary protection certificates in eighteen countries.
Summary for ELI LILLY AND CO
| International Patents: | 349 |
| US Patents: | 18 |
| Tradenames: | 10 |
| Ingredients: | 6 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for ELI LILLY AND CO: | See patent lawsuits for ELI LILLY AND CO |
| PTAB Cases with ELI LILLY AND CO as petitioner: | See PTAB cases with ELI LILLY AND CO as petitioner |
| PTAB Cases with ELI LILLY AND CO as patent owner: | See PTAB cases with ELI LILLY AND CO as patent owner |
Drugs and US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-003 | May 10, 2022 | RX | Yes | Yes | 11,045,474 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-007 | Mar 28, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-001 | May 13, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | 7,423,050 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | ZEPBOUND (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-001 | Nov 8, 2023 | RX | Yes | Yes | 11,357,820 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-001 | May 13, 2022 | RX | Yes | Yes | 11,357,820 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,590,213 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-003 | Jun 15, 1999 | 6,960,577 | ⤷ Sign Up |
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | 6,818,226 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-006 | Dec 23, 1992 | 6,960,577 | ⤷ Sign Up |
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 4,971,998*PED | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,018,895 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 6,960,577 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for ELI LILLY AND CO Drugs
Supplementary Protection Certificates for ELI LILLY AND CO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | PA2017023 | Lithuania | ⤷ Sign Up | PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2379528 | 9/2019 | Austria | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1307 (MITTEILUNG) 20181001 |
| 2379528 | C02379528/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66833 21.05.2019 |
| 2288610 | 2017C/025 | Belgium | ⤷ Sign Up | PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
| 2379528 | 2019C/507 | Belgium | ⤷ Sign Up | PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| 2288610 | C20170022 00232 | Estonia | ⤷ Sign Up | PRODUCT NAME: BARITSITINIIB;REG NO/DATE: EU/1/16/1170 15.02.2017 |
| 3242887 | LUC00296 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: TIRZEPATIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
